Moreover, it is reasonable to speculate that targeting fundamental plasticity genes, such as PSD-95, might not only be beneficial for treating AD, but also other brain disorders including HD and ALS, where the expression of this critical postsynaptic protein is also reduced (see Scheme 1). This evidence concerns the gene DLG4 and amyotrophic lateral sclerosis.